Alector, GSK Partner to Develop 2 Therapies for Dementia
Alector and GlaxoSmithKline (GSK) will collaborate in developing and commercializing two therapies aimed at treating an uncommon type of dementia that can cause problems with behavior and language. Both investigational therapies — AL001 and AL101 — can be used across a range of neurodegenerative disorders, including Parkinson’s,…